High-dose interleukin-2 in metastatic renal cell carcinoma - Reply

被引：0
|
作者：
McDermott, DF [1 ]
Atkins, MB
Regan, MM
机构：
[1] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 27期
关键词：
D O I：
10.1200/JCO.2005.02.2756
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6798 / 6799
页数：2
相关论文
共 50 条
  • [21] HIGH-DOSE INTERLEUKIN-2 2 DAYS A WEEK FOR METASTATIC RENAL-CELL CARCINOMA - A FNCLCC MULTICENTER STUDY
    ESCUDIER, B
    RAVAUD, A
    FABBRO, M
    DOUILLARD, JY
    NEGRIER, S
    CHEVREAU, C
    MIGNOT, L
    BAUME, D
    DORVAL, T
    VIGNAL, F
    FARACE, F
    MARANINCHI, D
    [J]. JOURNAL OF IMMUNOTHERAPY, 1994, 16 (04): : 306 - 312
  • [22] Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
    Ajjai Alva
    Gregory A. Daniels
    Michael K. K. Wong
    Howard L. Kaufman
    Michael A. Morse
    David F. McDermott
    Joseph I. Clark
    Sanjiv S. Agarwala
    Gerald Miletello
    Theodore F. Logan
    Ralph J. Hauke
    Brendan Curti
    John M. Kirkwood
    Rene Gonzalez
    Asim Amin
    Mayer Fishman
    Neeraj Agarwal
    James N. Lowder
    Hong Hua
    Sandra Aung
    Janice P. Dutcher
    [J]. Cancer Immunology, Immunotherapy, 2016, 65 : 1533 - 1544
  • [23] Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
    Alva, Ajjai
    Daniels, Gregory A.
    Wong, Michael K. K.
    Kaufman, Howard L.
    Morse, Michael A.
    McDermott, David F.
    Clark, Joseph I.
    Agarwala, Sanjiv S.
    Miletello, Gerald
    Logan, Theodore F.
    Hauke, Ralph J.
    Curti, Brendan
    Kirkwood, John M.
    Gonzalez, Rene
    Amin, Asim
    Fishman, Mayer
    Agarwal, Neeraj
    Lowder, James N.
    Hua, Hong
    Aung, Sandra
    Dutcher, Janice P.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2016, 65 (12) : 1533 - 1544
  • [24] High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features
    Achkar, Tala
    Arjunan, Ananth
    Wang, Hong
    Saul, Melissa
    Davar, Diwakar
    Appleman, Leonard J.
    Friedland, David
    Parikh, Rahul A.
    [J]. PLOS ONE, 2017, 12 (12):
  • [25] Clinical and Safety Profile of High-Dose Interleukin-2 Treatment in Elderly Patients with Metastatic Melanoma and Renal Cell Carcinoma
    Clark, James M.
    Kelley, Benjamin
    Titze, Jill
    Fung, Henry
    Maciejewski, John
    Nathan, Sunita
    Rich, Elizabeth
    Basu, Sanjib
    Kaufman, Howard L.
    [J]. ONCOLOGY, 2013, 84 (02) : 123 - 126
  • [26] Durable Response to Treatment With Combination Radiotherapy and High-dose Interleukin-2 in Metastatic Chromophobe Variant Renal Cell Carcinoma
    Merriman, Joseph
    Tward, Jonathan
    Albertson, Dan
    Dechet, Christopher
    Agarwal, Neeraj
    [J]. JOURNAL OF IMMUNOTHERAPY, 2016, 39 (02) : 101 - 103
  • [27] High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: The University of Chicago experience
    Shulman, KL
    Stadler, WM
    Vogelzang, NJ
    [J]. UROLOGY, 1996, 47 (02) : 194 - 197
  • [28] Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).
    Clark, Joseph
    Morse, Michael A.
    Wong, Michael K. K.
    McDermott, David F.
    Kaufman, Howard
    Daniels, Gregory A.
    Perritt, Jessica C.
    Hua, Hong
    Aung, Sandra
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [29] Survival advantage in patients treated with high-dose interleukin-2 (HDIL2) for metastatic renal cell carcinoma (mRCC)
    Lee, S.
    Baig, M.
    Rusciano, V.
    Gao, Y.
    Malik, S.
    Wiernik, P. H.
    Dutcher, J. P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] High Dose Interleukin-2 Therapy for Metastatic Renal Cell Carcinoma in the VEGF Targeted Era
    Fitzpatrick, A.
    Soosaipillai, G.
    Wilson, P.
    Powles, T.
    Shamash, J.
    [J]. CLINICAL ONCOLOGY, 2015, 27 (03) : E7 - E8
12345